polyclon
antibodi
centuryold
histori
effect
virus
recent
monoclon
antibodi
mab
also
shown
success
human
mab
synagi
palivizumab
remain
still
mab
respiratori
syncyti
viru
rsv
infect
approv
us
food
drug
administr
fda
recent
sever
potent
human
monoclon
antibodi
hmab
target
sever
acut
respiratori
syndromeassoci
coronaviru
sar
cov
glycoprotein
develop
quickli
viru
identifi
among
antibodi
exhibit
except
potenc
crossreact
neutral
isol
first
second
outbreak
palm
civet
vitroand
mice
similarli
first
fulli
hmab
two
paramyxovirus
hendra
viru
hev
nipah
viru
niv
caus
mortal
recent
develop
one
show
except
crossreact
potenc
niv
hev
threedimension
molecular
structur
envelop
glycoprotein
virus
complex
antibodi
receptor
recent
determin
structur
analys
along
experi
provid
insight
molecular
mechan
receptor
recognit
antibodi
neutral
suggest
antibodi
alon
combin
could
success
fight
virus
heterogen
mutabl
major
problem
develop
effect
therapeut
agent
virus
includ
therapeut
antibodi
antibodi
play
import
role
recoveri
protect
viral
infect
sera
human
anim
wide
use
prophylaxi
therapi
viral
bacteri
diseas
sinc
late
serum
therapi
bacteri
infect
abandon
antibiot
becam
wide
avail
howev
polyclon
antibodi
prepar
continu
use
toxinmedi
infecti
diseas
venom
bite
serum
immunoglobulin
continu
also
use
viral
diseas
treatment
avail
although
mostli
prophylaxi
either
prior
anticip
exposur
immedi
follow
exposur
infecti
agent
antibodi
product
licens
us
prevent
treatment
viral
diseas
includ
nonimmun
human
immunoglobulin
use
hepat
measl
virusspecif
polyclon
human
immunoglobulin
cytomegaloviru
hepat
b
rabi
respiratori
syncyti
viru
rsv
vaccinia
varicellazost
human
monoclon
antibodi
synagi
palivizumab
polyclon
immunoglobulin
also
use
variou
success
diseas
caus
human
virus
includ
parvoviru
pv
lassa
viru
west
nile
viru
enterovirus
herp
simplex
viru
crimeancongo
haemorrhag
fever
viru
cchfv
junin
viru
sever
acut
respiratori
syndromeassoci
coronaviru
sar
cov
human
immunodefici
viru
hiv
although
serum
polyclon
antibodi
prepar
clinic
effect
mani
case
problem
relat
toxic
includ
risk
allerg
reaction
lot
lot
variat
uncertain
dose
limit
use
monoclon
antibodi
mab
includ
chimer
animalhuman
human
fulli
human
monoclon
antibodi
hmab
lower
absent
immunogen
toxic
lot
lot
variat
molecular
mechan
therapeut
efficaci
antibodi
easier
dissect
engin
improv
therapeut
properti
recent
mab
shown
clinic
success
human
mab
synagi
still
mab
viral
diseas
approv
clinic
use
us
food
drug
administr
fda
wide
use
prevent
rsv
infect
neonat
immunecompromis
individu
recent
improv
howev
effect
treatment
alreadi
establish
infect
eg
signific
differ
clinic
outcom
placebo
palivizumab
group
children
hospit
rsv
infect
addit
resist
develop
rel
quickli
f
gene
resist
mutat
found
anim
model
rsv
infect
cotton
rat
week
infect
includ
complet
resist
viru
inde
envelop
virus
like
rsv
almost
without
except
neutral
antibodi
direct
viru
envelop
glycoprotein
project
surfac
virion
particl
tradit
antibodi
respons
immunolog
measur
viral
vaccin
efficaci
absenc
vaccin
effect
drug
develop
hmab
prophylaxi
treatment
emerg
virus
virus
biodefens
import
import
area
therapeut
develop
review
hmab
potenti
prophylaxi
treatment
diseas
caus
sar
cov
henipavirus
hendra
hev
nipah
niv
primari
focu
review
immunoglobulin
howev
isotyp
could
also
use
frequent
use
format
includ
antigenbind
fragment
fab
singl
chain
variabl
fragment
scfv
sometim
describ
sar
cov
caus
worldwid
epidem
infect
human
fatal
rate
although
recent
outbreak
need
develop
potent
therapeut
vaccin
reemerg
sar
cov
relat
viru
remain
high
import
sar
cov
surfac
glycoprotein
also
call
spike
glycoprotein
protein
glycoprotein
mediat
viral
entri
host
cell
two
function
domain
domain
involv
bind
cellular
receptor
wherea
domain
facilit
fusion
viral
host
cell
membran
infect
mani
virus
includ
coronavirus
elicit
potent
neutral
antibodi
nab
affect
cours
infect
help
clear
viru
also
protect
uninfect
host
expos
viru
sar
cov
except
nab
detect
sar
covinfect
patient
mice
hamster
monkey
infect
viru
antibodi
also
protect
uninfect
anim
sar
cov
infect
eg
passiv
transfer
immun
serum
naiv
mice
prevent
viru
replic
lower
respiratori
tract
follow
intranas
challeng
nab
serum
target
protein
includ
epitop
contain
portion
receptorbind
domain
rbd
conserv
fragment
limit
number
fragment
region
epitop
appear
conform
linear
one
studi
found
associ
linear
epitop
protein
ctermin
region
conform
epitop
ntermin
domain
immun
variou
antigen
also
induc
nab
mice
hamster
rabbit
ferret
pig
monkey
glycoprotein
alon
mediat
entri
sar
cov
therefor
mostli
use
immunogen
also
recent
found
nab
elicit
equal
efficaci
solubl
ectodomain
fulllength
membran
associ
protein
use
dna
immun
mice
without
boost
protein
xiao
biragyn
dimitrov
unpublish
data
studi
mice
immun
plasmid
dna
encod
full
length
spike
protein
rbd
fusion
protein
rbd
fc
elicit
high
serum
titer
protein
rbd
uml
sera
immun
mice
also
inhibit
proteinmedi
cell
fusion
inhibit
serum
dilut
neutral
activ
compar
sera
anim
immun
differ
form
rbd
data
suggest
rbd
protein
highli
immunogen
contain
epitop
neutral
antibodi
independ
whether
express
part
full
length
protein
solubl
rbd
also
confirm
role
rbd
immunodomin
domain
protein
target
neutral
antibodi
immun
mice
use
product
murin
neutral
monoclon
antibodi
nmab
two
sspecif
mab
demonstr
highest
vitro
neutral
potenc
subnanomolar
rang
appear
nmab
target
predominantli
conform
epitop
antibodi
convalesc
sar
patient
normal
human
serum
also
shown
specif
compet
bind
mab
whole
sar
cov
indic
exist
antibodi
infect
human
target
overlap
epitop
mous
nmab
potent
murin
nmab
eg
may
potenti
prevent
treatment
sar
especi
human
antibodi
avoid
possibl
immunogen
effect
nipah
viru
niv
hendra
viru
hev
close
relat
emerg
paramyxovirus
compris
henipavirusgenu
broad
speci
tropism
abil
caus
fatal
diseas
anim
human
distinguish
hev
niv
known
paramyxovirus
review
biolog
safeti
pathogen
niaid
biodefens
research
agenda
zoonot
emerg
categori
c
prioriti
pathogen
could
use
bioterror
agent
current
therapeut
modal
treat
niv
hev
infect
vaccin
prevent
diseas
human
livestock
popul
exist
although
antibodi
respons
detect
infect
caus
virus
mous
mab
isol
need
develop
hmab
specif
hev
niv
realiz
like
sar
cov
hev
niv
also
envelop
virus
possess
two
major
glycoprotein
spike
attach
g
glycoprotein
bind
viru
receptor
fusion
f
glycoprotein
facilit
fusion
viru
host
cell
membran
review
antibodi
specif
either
f
g
glycoprotein
neutral
viru
antibodi
specif
g
glycoprotein
appear
domin
target
antigen
neutral
antibodi
anim
human
infect
either
hev
niv
develop
neutral
antibodi
recent
bioplex
platform
assay
develop
recombin
solubl
g
sg
glycoprotein
hev
niv
use
antigen
allow
simultan
detect
differenti
hev
niv
specif
neutral
antibodi
sera
natur
infect
immun
sourc
sinc
f
g
glycoprotein
major
target
nab
use
antigen
compon
vaccin
explor
addit
natur
host
fli
fox
niv
natur
infect
pig
hors
cat
dog
human
experiment
infect
guinea
pig
hamster
cat
niv
also
demonstr
review
contrast
hev
appear
less
transmiss
natur
natur
acquir
infect
bat
hors
human
describ
experiment
hev
infect
guinea
pig
cat
review
use
smaller
anim
model
studi
pathogenisi
aid
efficaci
studi
vaccin
therapeut
problemat
hev
niv
neither
viru
appear
capabl
infect
caus
reproduc
diseas
mice
rabbit
infect
guinea
pig
also
met
variabl
result
date
small
anim
model
use
niv
golden
hamster
review
present
among
report
find
golden
hamster
cat
repres
avail
suitabl
anim
model
examin
sever
pathogen
process
niv
hev
infect
use
challeng
experi
evalu
potenti
antivir
therapeut
review
vaccin
challeng
studi
niv
carri
hamster
model
use
recombin
vaccinia
virus
encod
fulllength
niv
f
g
expect
approach
elicit
neutral
antibodi
niv
abl
protect
anim
lethal
diseas
although
effect
neither
platform
like
viabl
vaccin
candid
use
human
classif
highli
pathogen
natur
develop
liveattenu
hev
niv
vaccin
also
doubt
howev
recombin
subunit
immunogen
could
viabl
approach
niv
hev
vaccin
extrem
safe
administ
risk
infect
recombin
sg
hev
niv
glycoprotein
explor
vaccin
immunogen
sg
shown
retain
sever
structur
function
antigen
characterist
similar
nativ
g
includ
oligomer
receptor
bind
compet
elicit
strong
polyclon
neutral
antibodi
respons
rabbit
mice
cat
immun
either
niv
hev
sg
exhibit
high
homolog
serum
neutral
titer
although
immunogen
elicit
signific
level
heterolog
crossreact
neutral
titer
anim
given
hev
sg
yield
higher
crossreact
respons
immun
cat
complet
protect
lethal
challeng
niv
provid
evid
success
subunit
vaccin
also
singl
vaccin
hev
sg
could
use
protect
hev
niv
evid
abil
hev
g
elicit
crossreact
antibodi
respons
recent
provid
bossart
et
al
analysi
antibodi
respons
sera
natur
infect
immun
sourc
reveal
although
specif
respons
g
mirror
infect
viru
hevinfect
individu
high
level
niv
g
crossreact
antibodi
nivinfect
individu
limit
crossreact
antibodi
hev
g
interestingli
describ
latter
part
text
pan
phagedisplay
antibodi
librari
hev
g
mimic
aspect
vivo
immun
result
select
highaffin
potent
neutral
antibodi
niv
togeth
characterist
g
recombin
sg
suggest
would
ideal
antigen
purpos
elicit
isol
neutral
human
monoclon
antibodi
nhmab
addit
activ
vaccin
evid
passiv
deliv
antibodi
protect
niv
challeng
demonstr
hamster
use
pool
monospecif
polyclon
antiserum
f
g
although
amount
serum
larg
sera
viru
administ
close
success
intraperiton
inject
studi
demonstr
neutral
antibodi
viral
envelop
glycoprotein
niv
protect
lethal
diseas
followup
studi
group
use
two
murin
mab
niv
f
two
g
passiv
immunotherapi
also
conduct
use
hamster
mab
administ
ascit
fluid
intraperiton
inject
sever
version
protocol
carri
vari
amount
time
administr
anim
receiv
mab
suffici
amount
immedi
follow
intraperiton
challeng
niv
complet
protect
high
level
either
antig
antif
mab
seem
afford
steril
immun
lower
amount
antibodi
result
measur
increas
antiniv
antibodi
follow
viru
challeng
could
still
protect
fatal
infect
studi
also
support
notion
passiv
immunotherapi
direct
viral
envelop
glycoprotein
could
viabl
treatment
niv
infect
howev
passiv
immun
experi
use
antibodi
administ
system
follow
viru
challeng
yet
evalu
human
murin
mab
formul
accept
therapeut
product
human
use
take
consider
effort
sever
group
recent
develop
hmab
sar
cov
glycoprotein
neutral
viru
potenti
therapi
prophylaxi
sar
review
recent
improv
method
epsteinbarr
viru
ebv
transform
human
b
cell
develop
base
cpg
oligonucleotid
cpg
increas
b
cell
immort
effici
method
use
select
hmab
specif
sar
cov
protein
one
select
antibodi
specif
glycoprotein
viral
spike
effici
neutral
convalesc
serum
prevent
cytopath
effect
sar
cov
ngml
inhibit
entri
pseudoviru
glycoprotein
urbani
isol
ic
howev
affect
signific
extent
pseudoviru
entri
mediat
isol
glycoprotein
even
enhanc
entri
viru
pseudotyp
glycoprotein
palm
civet
isol
mous
model
sar
cov
infect
antibodi
prevent
viral
replic
lower
respiratori
tract
dose
reduc
upper
respiratori
tract
highest
dose
use
data
vivo
neutral
activ
nhmab
select
studi
includ
potent
antibodi
neutral
concentr
ngml
lower
report
articl
high
neutral
activ
two
hmab
format
indic
possibl
use
alon
combin
prophylaxi
treatment
sar
phage
display
technolog
increasingli
use
produc
high
affin
hmab
immun
librari
advantag
use
librari
b
lymphocyt
infect
immun
host
requir
recent
two
human
nonimmun
scfv
librari
contain
member
develop
b
cell
unimmun
donor
use
select
antibodi
purifi
fragment
contain
residu
one
select
antibodi
neutral
viru
microneutr
assay
concentr
low
nm
also
block
format
syncytia
could
contribut
spread
viru
vivo
although
significantli
higher
concentr
nm
epitop
overlap
bind
site
sar
cov
receptor
suggest
possibl
mechan
neutral
prevent
viru
attach
receptor
given
prophylact
mice
dose
therapeut
achiev
human
viral
replic
reduc
assay
limit
one
note
condit
use
evalu
neutral
activ
differ
antibodi
studi
exactli
studi
describ
also
thu
compar
activ
differ
antibodi
done
caution
unless
test
side
side
exactli
condit
three
neutral
hmab
also
select
anoth
larg
antibodi
librari
bound
recombin
fragment
compris
amino
acid
residu
region
previous
identifi
sar
rbd
rbd
potent
hnmab
requir
residu
rbd
bind
antibodi
exhibit
vitro
neutral
activ
importantli
antibodi
show
neutral
activ
ferret
one
set
experi
ferret
inocul
either
viru
two
dose
low
tcid
high
tcid
viru
preincub
antibodi
mgml
low
dose
mgml
high
one
anim
expos
virusantibodi
mixtur
almost
undetect
sar
cov
lung
show
lung
lesion
day
shed
viru
throat
unlik
control
anim
treat
irrelev
antibodi
second
set
experi
antibodi
mgkg
administ
h
challeng
viru
reach
serum
concentr
three
anim
fourth
one
three
ferret
high
antibodi
concentr
viru
shed
throat
complet
abolish
fourth
one
compar
control
group
treat
anim
log
lower
mean
viru
titer
control
complet
protect
macroscop
lung
patholog
note
antibodi
dose
use
mgkg
less
one
mgkg
use
prevent
rsv
infect
infant
administ
month
recent
vitro
sarscov
variant
escap
neutral
gener
singl
mutat
glycoprotein
escap
viru
vitro
experi
confirm
bind
recombin
fragment
amino
acid
residu
harbor
mutat
abolish
antibodyphag
librari
deriv
blood
convalesc
sar
patient
screen
antibodi
complementari
novel
mab
identifi
neutral
escap
virus
compet
bind
recombin
fragment
bound
fragment
deriv
civet
cat
sarscovlik
strain
escap
variant
could
gener
mixtur
mab
show
neutral
sarscov
synergist
fashion
recogn
differ
epitop
rbd
mechan
remain
unknown
dose
reduct
indic
observ
respect
neutral
result
suggest
potenti
use
combin
prophylaxi
sar
cov
infect
human
howev
one
note
current
avail
anim
model
sar
cov
infect
result
death
human
two
hmab
deriv
transgen
mice
human
ig
gene
evalu
murin
model
sar
cov
infect
one
antibodi
bound
within
rbd
protein
amino
acid
residu
one
bound
region
contain
residu
microneutr
assay
base
protect
cytopath
effect
ic
mice
receiv
mgkg
antibodi
prior
challeng
sar
cov
complet
protect
viru
replic
lung
dose
low
mgkg
offer
signific
protect
antibodi
potenti
therapeut
research
tool
recent
novel
crossreact
potent
sar
covneutr
hmab
identifi
use
fragment
contain
residu
select
antigen
pan
larg
human
antibodi
librari
construct
b
lymphocyt
healthi
volunt
fragment
previous
identifi
contain
rbd
major
sar
cov
neutral
determin
sar
cov
caus
two
outbreak
epidem
late
second
outbreak
winter
independ
animaltohuman
transmiss
antibodi
test
isol
outbreak
anim
host
initi
outbreak
strain
isol
index
patient
second
outbreak
report
resist
neutral
hmab
potent
neutral
isol
first
outbreak
found
anoth
antibodi
potent
neutral
repres
isol
first
sar
outbreak
urbani
palm
civet
antibodi
also
protect
mice
challeng
urbani
recombin
virus
bear
glycoprotein
antibodi
compet
sar
cov
receptor
bind
rbd
suggest
mechan
neutral
involv
interfer
sar
interact
antibodi
first
identifi
hmab
exhibit
crossreact
isol
two
sar
outbreak
palm
civet
could
potenti
applic
diagnosi
prophylaxi
treatment
sar
cov
infect
nab
direct
inhibit
sar
cov
entri
either
interf
typic
rbdreceptor
interact
mechan
includ
bind
portion
human
scfv
identifi
recogn
epitop
protein
locat
within
amino
acid
antibodi
recogn
sar
pseudoviru
vivo
compet
sar
sera
bind
sar
cov
equilibrium
dissoci
constant
k
nm
also
potent
neutral
activ
infect
pseudoviru
express
sar
cov
protein
vitro
mechan
sar
cov
infect
inhibit
could
includ
steric
hindranc
indirectli
prevent
viru
attach
receptor
bind
entri
intermedi
mechan
could
oper
vivo
lack
data
discuss
relat
antibodi
biolog
effector
function
confer
antibodi
fc
eg
antibodydepend
cellular
cytotox
adcc
interact
block
antibodi
target
either
inde
found
antibodi
antibodi
block
viral
replic
vero
cell
receptor
host
molecul
mutat
use
antibodi
target
receptor
molecul
may
prevent
gener
resist
mutant
howev
appear
sar
cov
infect
acut
infect
gener
resist
mutant
may
signific
problem
although
recent
identif
bat
natur
reservoir
sar
cov
suggest
possibl
larg
variat
sequenc
virus
could
transmit
human
addit
antibodi
could
affect
function
cell
experi
anim
model
requir
find
whether
sar
cov
infect
presenc
nhmab
lead
gener
neutral
escap
mutant
whether
nhmab
antibodi
deleteri
effect
host
recent
year
substanti
amount
structur
inform
mechan
sar
cov
entri
neutral
crossreact
made
avail
crystal
structur
complex
reveal
structur
rbd
interact
receptor
figur
rbd
fivestrand
antiparallel
core
extend
loop
support
twostrand
segreg
separ
core
receptor
interact
buri
interfac
predominantli
made
hydrophil
side
chain
includ
six
tyrosin
rbd
crystal
structur
fab
complex
rbd
determin
resolut
figur
antibodi
epitop
domin
protrud
loop
loop
compris
residu
promin
protrud
rbd
surfac
contact
four
cdr
complementaritydeterminingregion
fab
total
surfac
area
buri
interfac
complex
antibodybind
loop
alon
account
rbdantibodi
interfac
crystal
structur
antisar
scfv
antibodi
complex
rbd
also
determin
antibodi
complex
structur
figur
interfac
buri
rel
larg
surfac
bind
involv
six
cdr
loop
well
major
portion
framework
region
loop
comparison
complex
structur
provid
import
clue
structur
mechan
antibodymedi
neutral
crossreact
observ
antibodi
fab
scfv
well
receptor
occupi
common
region
surfac
rbd
color
red
figur
c
mainli
consist
loop
rbd
therefor
residu
loop
rbd
critic
bind
antibodi
receptor
closeup
view
loop
rbd
correspond
rbd
complex
shown
figur
f
residu
loop
play
critic
role
contact
receptor
antibodi
receptor
complex
rbd
contact
figur
determin
speci
specif
human
civet
mous
rat
antibodi
complex
rbd
bind
antibodi
combin
site
cdr
loop
heavi
chain
figur
observ
demonstr
antibodi
neutral
sar
cov
compet
set
critic
residu
loop
rbd
therefor
block
receptor
bind
site
note
residu
identifi
put
hot
spot
rbd
within
sar
cov
spike
like
contribut
bind
energi
residu
highli
conserv
within
sar
cov
spike
indic
possibl
mechan
crossreact
sequenc
analysi
mutagenesi
data
show
might
neutral
zoonot
epidem
sar
cov
isol
known
sequenc
except
strain
deriv
bat
intriguingli
either
unligand
rbd
depict
antibodybound
rbd
significantli
differ
rbd
suggest
lockandkey
mechan
antibodi
bind
site
lack
rbd
conform
chang
induc
domain
import
implic
mechan
entri
major
neutral
determin
locat
contigu
one
major
segment
loop
antibodi
complex
wherea
antibodi
receptor
determin
extend
loop
appear
top
rbd
differ
lead
critic
effect
differenti
specif
sensit
antibodi
exampl
rbd
found
contact
residu
mutat
complet
abrog
bind
mutat
affect
antibodi
bind
epitop
includ
residu
antibodi
potent
neutral
viru
pseudotyp
glycoprotein
guangdong
index
patient
isol
compar
middlel
phase
isol
five
residu
rbd
mutat
late
isol
includ
among
five
residu
contact
antibodi
combin
site
observ
structur
howev
complex
structur
make
backbon
contact
therefor
mutat
would
affect
significantli
bind
antibodi
thu
abl
neutral
sar
cov
isol
known
sequenc
appear
broadli
crossreact
neutral
antibodi
sar
cov
identif
potent
neutral
hmab
target
viral
envelop
glycoprotein
g
use
highli
purifi
oligomer
solubl
hev
g
sg
glycoprotein
antigen
screen
larg
human
phagedisplay
librari
recent
report
select
seven
fab
inhibit
variou
degre
cell
fusion
mediat
hev
niv
env
viru
infect
convers
potent
neutral
infecti
hev
fab
significantli
increas
cell
fusion
inhibitori
activ
ic
decreas
approxim
also
except
potent
neutral
infecti
hev
complet
neutral
achiev
neutral
requir
inhibit
fusion
infect
correl
bind
fab
fulllength
g
measur
immunoprecipit
less
bind
sg
measur
elisa
biacor
antibodi
compet
identifi
function
receptor
hev
niv
indic
possibl
mechan
neutral
antibodi
observ
antibodi
compet
suggest
bind
overlap
epitop
distinct
epitop
initi
attempt
local
epitop
analyz
solv
complex
structur
nipah
hendra
attach
g
glycoprotein
receptor
crystal
structur
niv
g
complex
hev
g
complex
depict
figur
respect
nivg
hydrophob
pocket
form
residu
residu
gh
loop
fit
hydrophob
pocket
surfac
niv
g
glycoprotein
figur
hevg
also
similar
hydrophob
pocket
gh
loop
insert
figur
note
similar
virusreceptor
structur
interact
hiv
glycoprotein
receptor
well
hiv
interact
antibodi
hiv
interact
c
c
loop
receptor
make
critic
contact
reach
hydrophob
pocket
form
inner
outer
domain
figur
complex
antibodi
cdr
loop
antibodi
fit
hydrophob
pocket
surfac
similar
manner
receptor
interact
figur
comparison
glycoprotein
complex
structur
receptor
antibodi
would
suggest
epitop
might
overlap
bind
site
nivhev
g
attach
glycoprotein
close
proxim
residu
could
affect
steric
block
ephrin
receptor
bind
recent
affin
matur
version
cross
reactiv
antibodi
design
develop
chain
shuffl
phage
display
librari
pan
antibodi
show
significantli
improv
neutral
activ
nipah
hendra
virus
vitro
respect
result
suggest
especi
exhibit
potent
crossreact
neutral
activ
nipah
viru
hendra
viru
first
hmab
identifi
virus
could
use
treatment
prophylaxi
diagnosi
research
reagent
aid
develop
vaccin
hmab
direct
sar
cov
glycoprotein
henipaviru
g
glycoprotein
current
advanc
stage
develop
offer
best
hope
potenti
therapeut
antibodi
specif
sar
cov
hev
niv
potenti
develop
clinic
use
product
prophylaxi
perhap
treatment
diseas
caus
infect
potent
crossreact
viral
infect
specif
acut
control
dampen
viru
replic
rel
short
period
time
week
two
like
requir
host
immun
system
could
control
viru
replic
thu
problem
neutral
resist
mutant
abl
evad
inhibitori
activ
immun
respons
signific
chronic
infect
high
level
viru
replic
eg
hiv
infect
note
caution
care
examin
candid
antibodi
therapeut
requir
possibl
infect
enhanc
effect
anim
modeldepend
effect
well
case
although
rare
toxic
recent
studi
also
report
possibl
neutral
antibodi
enhanc
entri
sar
cov
mechan
involv
antibodi
interact
conform
epitop
rbd
addit
known
case
antibodi
neutral
assay
current
use
evalu
vitro
activ
could
exhibit
potent
neutral
activ
vivo
thu
new
approach
develop
antibodi
test
also
effector
function
mediat
fc
includ
adcc
compliment
mediat
immun
respons
howev
explor
antibodi
extens
evalu
anim
model
like
combin
antivir
drug
antibodi
small
molecul
would
allow
identif
best
candid
potenti
therapeut
aniv
g
complex
niv
g
magenta
yellow
show
domin
virusreceptor
interact
involv
gh
loop
snugli
fit
hydrophob
pocket
shown
gray
surfac
portion
niv
g
glycoprotein
bhev
g
complex
hev
g
green
cyan
gh
ephrin
loop
insert
channel
shown
red
surfac
niv
g
chiv
glycoprotein
red
complex
receptor
yellow
extract
hiv
ternari
complex
domain
antibodi
shown
c
c
loop
make
critic
contact
reach
hydrophob
pocket
shown
gray
surfac
form
inner
outer
domain
red
complex
antibodi
partli
shown
heavi
chain
blue
light
chain
pink
cdr
loop
antibodi
fit
hydrophob
pocket
surfac
gray
similar
manner
receptor
interact
phage
display
domain
mous
bound
nanomolar
affin
block
bind
xray
structur
scfv
sar
cov
rbd
complex
known
epitop
spars
overlap
bind
site
phage
display
domain
ferret
domain
critic
antibodi
bind
expert
opin
biol
ther
author
manuscript
avail
pmc
march
